Enterostatin
Overview
|
WikiDoc Resources for Enterostatin |
|
Articles |
|---|
|
Most recent articles on Enterostatin Most cited articles on Enterostatin |
|
Media |
|
Powerpoint slides on Enterostatin |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Enterostatin at Clinical Trials.gov Clinical Trials on Enterostatin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Enterostatin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Enterostatin Discussion groups on Enterostatin Patient Handouts on Enterostatin Directions to Hospitals Treating Enterostatin Risk calculators and risk factors for Enterostatin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Enterostatin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Enterostatin is a pentapeptide produced from exocrine pancreas and gastrointestinal tract that selectively reduces fat intake. Its effects include a reduction of insulin secretion, an increase in sympathetic drive to brown adipose tissue, and the stimulation of adrenal corticosteroid secretion. At the end level, it initiates a sensation of fullness of stomach which could be the reason for its role in regulation of fat intake and reduction of body weight.